Recent advances in mass spectrometry have opened new avenues in disease research and detection, including targeted protein analysis, which elevates our understanding of health and disease. Mass spectrometry can help ensure development of accurate, reproducible, and robust methods that translate targeted scientific discoveries into the clinical diagnostic and therapeutic setting.
Disease and disorders research primary focus:
- Understanding proteomic, metabolomic, lipidomic, or genomic profiles in the presence of the virus/disease
- Monitoring therapeutic influence for potential biomarkers
- Monitoring critical and targeted viral and/or human plasma proteins to determine and predict the extent of infection
Targeted protein quantitation with mass spectrometry plays an important role in developing therapeutic strategies, vaccine development, variant detection, virology, and disease pathogenesis.
Clinical Research resources on this page
Infectious diseases, including SARS-CoV-2 (COVID-19)
For research in infectious diseases, including the study of viral antigens and nucleic acids and detection of virus-specific antibodies in blood samples, liquid chromatography (LC) coupled to mass spectrometry (MS) technology can achieve and deliver outstanding confidence in results.
Mass spectrometry (MS) can provide insights into viral behavior by studying intact viral particles as well as their surfaces and binding characteristics, protein compositions, and their impacts on the biochemical pathways of host cells upon infection.
Cardiac disease
When identifying biotherapeutic targets, understanding signaling pathways, and detecting heart diseases that arise from other conditions, LC-MS technology can be used to study proteins and metabolites targeting post translational modifications, pathophysiological signaling, and anatomical specificity.
Inborn errors of metabolism (IEM)
Because most conditions detected by newborn screening arise from metabolic and genetic disorders that are inherited or may show up in a family for the first time, early detection by LC-MS can facilitate prompt intervention and treatment to prevent physical disabilities and life-threatening illness.
Breath biopsy for early disease detection
In collaboration with Owlstone Medical, the development of a non-invasive Breath Biopsy™ approach for disease detection is underway to enable early disease detection through discovery of novel biomarkers using TD-GC-Orbitrap mass spectrometry technology. Compared to genomics and other -omics approaches, studying breath VOCs, so-called 'breathomics,' reveals the current health status of cells, tissues, and the microbiome.
By determining the chemical compounds present in exhaled volatile organic compounds, researchers can identify biomarkers of disease and detect diseases in their earliest stages. Explore the breath analysis workflow ›
Additional research on important diseases
In orphan disease, diabetes, tuberculosis (TB), and Zika, LC-MS is playing a pivotal role in focusing on expression of critical proteomes responding to infection, monitoring proteoform distribution by comparison, and identifying critical peptides that are unique to infected individuals.
Learn how LC/MS plays a role in understanding diseases.
Sample workflow of mass spectrometry-based analysis of infectious disease samples
LC-MS enables accurate targeted protein quantitation in disease research.
Explore the LC-MS COVID-19 workflow in action
Resources
See other LC-MS disease assays developed by our customers: Peer-reviewed articles
For General Lab Use Only. Not for use in diagnostic procedures.
